Darizmetinib
CAS No. 2369583-33-3
Darizmetinib( —— )
Catalog No. M36482 CAS No. 2369583-33-3
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 151 | In Stock |
|
| 2MG | 91 | In Stock |
|
| 5MG | 150 | In Stock |
|
| 10MG | 236 | In Stock |
|
| 25MG | 342 | In Stock |
|
| 50MG | 414 | In Stock |
|
| 100MG | 606 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDarizmetinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionDarizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
-
DescriptionDarizmetinib is an inhibitor of mitogen-activated protein kinase kinase (MAP2K).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorMAPK | Antiviral
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2369583-33-3
-
Formula Weight457.45
-
Molecular FormulaC21H17F2N5O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C1=NNC2=NC=C(C=C21)C=3C=CN=CC3)C4=CC=C(F)C(NS(=O)(=O)CCC)=C4F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Praefke B, et al. Preparation of pyrazolopyridines as protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death: World Intellectual Property Organization, WO2019149738. 2019-08-08.
molnova catalog
related products
-
p38α inhibitor 4
p38α inhibitor 4 is a selective MAPK p38α inhibitor, which is used to study diabetes, pain and chronic inflammation.
-
LY2228820 dimesylate
LY2228820 dimesylate (Ralimetinib) is a potent, selective, orally available inhibitor p38 MAPK with IC50 of 5.3 and 3.2 nM for p38α and p38β, respectively.
-
16,17-Epoxypregnenol
16,17-Epoxypregnenol
Cart
sales@molnova.com